ArticleBreast cancer research and treatment2026
Investigation of DNA methylation levels before and after treatment in breast cancer patients receiving neoadjuvant chemotherapy.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeDrug resistance is a major cause of treatment failure in breast cancer patients. Numerous genetic and epigenetic markers have been proposed to influence Neoadjuvant Chemotherapy (NACT) response, and genes that regulate the effectiveness of chemotherapeutic agents undergo expression regulation via methylation. In this study, we aimed to investigate the methylation levels of KDM5A, KDM5B, and KDM5C, as well as their associated genes, EZH2, TFAP2C, ZMYND8, and SIN3B (Exon 1-2 and 19-20), in blood samples collected from patients before and after NACT treatment. Besides, we also examined potential variations in the KDM5A, KDM5B, and KDM5C gene regions.
methodsTwenty patients were diagnosed with breast cancer, and 30 healthy control individuals were included in the study. Blood samples were taken from the patients twice, before and after NACT. Methylation levels of KDM5 family genes and related genes were analyzed using Methylation-specific PCR (MSP). Additionally, potential variants in the KDM5A, KDM5B, and KDM5C gene regions were identified using Sanger sequencing.
resultsAccording to the methylation analysis results, the SIN3B (Exon 19-20), KDM5C, EZH2, and TFAP2C genes were prominent in patients with pathological partial response, while the KDM5A, KDM5B, KDM5C, EZH2, TFAP2C, and SIN3B (Exon 19-20) genes were prominent in patients with pathological complete response. According to genotyping results, rs41308616 and rs971896841 variants were detected as heterozygous in the KDM5C gene region in two patients, respectively.
conclusionThe methylation percentages and genetic variations in the KDM5 family and related gene regions identified in this study may serve as potential biomarkers for developing treatment strategies for breast cancer patients.
Indexed as
Identifiers
42894051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.